PHAT earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E -5.52. Updated 2026-07-23.
Phathom Pharmaceuticals (PHAT) Research Hub
Phathom Pharmaceuticals (PHAT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 8.36 USD (-3.58%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.52, market cap 0.91B. This hub links to the full technical, earnings and options research available for PHAT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 8.36 USD (-3.58%) |
| 52-week range | 8.07 USD – 12.64 USD |
| Trend regime | Range |
| 14-day RSI | 47.6 (Neutral) |
| Trailing P/E | -5.52 |
| Market cap | 0.91B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for PHAT
Covered Call on PHAT: how it works, illustrative setup around the real 8.36 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PHAT: how it works, illustrative setup around the real 8.36 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PHAT: how it works, illustrative setup around the real 8.36 USD price, max profit/loss, breakeven and when to use it. Educational.
PHAT technical analysis: range, last 8.36 USD, RSI 47.6, 52w range 8.07 USD–12.64 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PHAT in?
Phathom Pharmaceuticals (PHAT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PHAT in an uptrend or downtrend?
As of 2026-09-11, PHAT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PHAT's trailing P/E ratio?
PHAT's trailing P/E is -5.52, with a market cap of 0.91B. See the earnings research page for full valuation detail.
When does PHAT next report earnings?
PHAT is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of -0.06 USD.